Fulcrum Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -216 | -338 | 300 | -14,296 |
EBITDA | -19,690 | -18,553 | -19,987 | -19,249 |
EBIT | -19,906 | -18,891 | -20,334 | -19,595 |
Net Income | -26,179 | -18,891 | -20,334 | -19,595 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -16,147 | -18,758 | -16,957 | -14,280 |
Cash | 48,466 | 50,261 | 197,533 | 47,078 |
Basic Shares | 76,264 | 76,215 | 63,355 | 62,597 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $80,000 | $2,805 | $6,342 |
Gross Profit | -1,390 | 16,614 | -68,996 | -70,440 |
EBITDA | -73,490 | -18,241 | -95,163 | -109,720 |
EBIT | -74,880 | -19,834 | -97,335 | -112,134 |
Net Income | -74,880 | -9,725 | -97,335 | -109,871 |
Net Change In Cash | 0 | 80,000 | 2,805 | 6,342 |
Cost of Revenue | -314 | |||
Free Cash Flow | -60,379 | -2,496 | -91,473 | -99,013 |
Cash | 197,533 | 58,212 | 25,563 | 35,098 |
Basic Shares | 63,355 | 61,984 | 61,310 | 44,991 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.28 |
2026-03-31 | -$0.25 |
2025-12-31 | -$0.31 |
2025-09-30 | -$0.31 |